| consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Alimentary pharmacology & therapeutics 46 (11-12), 1037-1053, 2017 | 274 | 2017 |
| Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey M Cheema, N Mitrev, L Hall, M Tiongson, G Ahlenstiel, V Kariyawasam BMJ open gastroenterology 8 (1), e000581, 2021 | 52 | 2021 |
| IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti … N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Aliment Pharmacol Ther 46 (11-12), 1037-53, 2017 | 50 | 2017 |
| Medication non-adherence in inflammatory bowel diseases is associated with disability J Perry, A Chen, V Kariyawasam, G Collins, C Choong, WL Teh, N Mitrev, ... Intestinal research 16 (4), 571, 2018 | 48 | 2018 |
| Hygiene hypothesis: is the evidence the same all over the world? RW Leong, N Mitrev, Y Ko Digestive diseases 34 (1-2), 35-42, 2016 | 43 | 2016 |
| Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease N Mitrev, RW Leong Expert Opinion on Drug Safety 16 (3), 303-317, 2017 | 35 | 2017 |
| Review of exclusive enteral therapy in adult Crohn’s disease N Mitrev, H Huang, B Hannah, VC Kariyawasam BMJ open gastroenterology 8 (1), e000745, 2021 | 28 | 2021 |
| infliximab trough cut‐off for perianal Crohn's disease–another piece of the therapeutic drug monitoring‐guided infliximab dosing puzzle N Mitrev, V Kariyawasam, RW Leong Alimentary pharmacology & therapeutics 45 (9), 1279-1280, 2017 | 8 | 2017 |
| Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis VC Kariyawasam, FH Mourad, N Mitrev, S Paramsothy, CP Selinger, ... European Journal of Gastroenterology & Hepatology 33 (12), 1524-1532, 2021 | 6 | 2021 |
| Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature M Au, N Mitrev, RW Leong, V Kariyawasam World Journal of Clinical Cases 10 (8), 2569, 2022 | 5 | 2022 |
| Adolescents and young adults communicating with gastroenterologists: variation in inflammatory bowel disease clinical communication N Karimi, A Lukin, AR Moore, JL Pipicella, R Kanazaki, AJ Williams, W Ng, ... International Journal of Adolescent Medicine and Health 35 (4), 347-361, 2023 | 1 | 2023 |
| Access to inflammatory bowel disease nurses and education is associated with less stress, anxiety, and depression: Australian national inflammatory bowel disease survey M Cheema, N Mitrev, M Toingson, G Ahlenstiel, L Hall, VC Kariyawasam | 1 | 2020 |
| Therapeutic drug monitoring guided anti-tumour necrosis factor therapy in inflammatory bowel disease (IBD): Gastroenterological Society of Australia (GESA)/Australian IBD … N Mitrev | 1 | 2017 |
| Treatment endpoints in ulcerative colitis: Does one size fit all? N Mitrev, V Kariyawasam World Journal of Gastrointestinal Pharmacology and Therapeutics 15 (2), 2024 | | 2024 |
| Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study D Huang, M Rennie, A Krasovec, S Nagubandi, S Liu, E Ge, B Khehra, ... Therapeutic Advances in Chronic Disease 15, 20406223241233203, 2024 | | 2024 |
| S1183 Exclusive Enteral Nutrition Among Adult Patients With Active Crohn’s Disease: A Single Center Experience A Sheiban, B Maguire, M Ghali, N Premachandra, K Niazi, B Baraty, ... Official journal of the American College of Gastroenterology| ACG 118 (10S …, 2023 | | 2023 |
| Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a … M Au, P Low, M Rennie, M Mohseni, Y Song, N Kim, B Baraty, N Mitrev, ... BMJ open 13 (7), e073843, 2023 | | 2023 |
| Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE … YK An, N Lindsay, N Allan, E Khoo, R Fernandes, A Amiss, H Pham, ... Gastroenterology 164 (6), S-1108, 2023 | | 2023 |
| Su1733 BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF … YK An, N Lindsay, N Allan, E Khoo, R Fernandes, A Amiss, H Pham, ... Gastroenterology 164 (6), S-657-S-658, 2023 | | 2023 |
| P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients … YK An, N Lindsay, N Allan, E Khoo, R Fernandes, A Amiss, H Pham, ... Journal of Crohn's and Colitis 17 (Supplement_1), i793-i794, 2023 | | 2023 |
